Deutsche Bank AG set a $21.00 price objective on Impax Laboratories, Inc. (NASDAQ:IPXL) in a research report sent to investors on Monday, July 17th. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
A number of other research firms have also recently commented on IPXL. Royal Bank Of Canada reiterated an outperform rating and set a $62.00 target price (up previously from $10.00) on shares of Impax Laboratories in a research report on Thursday, May 11th. Zacks Investment Research upgraded Impax Laboratories from a hold rating to a buy rating and set a $19.00 target price on the stock in a research report on Tuesday, July 11th. BidaskClub upgraded Impax Laboratories from a hold rating to a buy rating in a research report on Wednesday, July 12th. BMO Capital Markets reiterated a hold rating and set a $16.00 target price on shares of Impax Laboratories in a research report on Friday, June 23rd. Finally, Janney Montgomery Scott reiterated a neutral rating and set a $21.00 target price on shares of Impax Laboratories in a research report on Monday, June 12th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $18.56.
Shares of Impax Laboratories (NASDAQ:IPXL) traded up 0.55% during midday trading on Monday, reaching $18.30. The company’s stock had a trading volume of 1,600,694 shares. Impax Laboratories has a one year low of $7.75 and a one year high of $27.29. The company’s market capitalization is $1.31 billion. The stock’s 50-day moving average is $17.34 and its 200-day moving average is $14.34.
Impax Laboratories (NASDAQ:IPXL) last posted its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 EPS for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.04. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The business had revenue of $202.08 million for the quarter, compared to analysts’ expectations of $195.62 million. During the same quarter in the previous year, the firm earned $0.21 earnings per share. The business’s revenue was up 17.1% compared to the same quarter last year. On average, equities analysts expect that Impax Laboratories will post $0.68 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/13/impax-laboratories-inc-nasdaqipxl-given-a-21-00-price-target-by-deutsche-bank-ag-analysts-updated-updated-updated.html.
Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Impax Laboratories by 9.1% in the second quarter. Vanguard Group Inc. now owns 6,821,118 shares of the specialty pharmaceutical company’s stock worth $109,820,000 after buying an additional 569,723 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Impax Laboratories by 23.0% in the second quarter. Dimensional Fund Advisors LP now owns 3,244,580 shares of the specialty pharmaceutical company’s stock worth $52,238,000 after buying an additional 607,503 shares in the last quarter. North Tide Capital LLC raised its stake in shares of Impax Laboratories by 50.0% in the first quarter. North Tide Capital LLC now owns 3,000,000 shares of the specialty pharmaceutical company’s stock worth $37,950,000 after buying an additional 1,000,000 shares in the last quarter. Frontier Capital Management Co. LLC raised its stake in shares of Impax Laboratories by 43.2% in the second quarter. Frontier Capital Management Co. LLC now owns 1,585,828 shares of the specialty pharmaceutical company’s stock worth $25,532,000 after buying an additional 478,168 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Impax Laboratories during the fourth quarter worth $16,669,000. 83.48% of the stock is currently owned by institutional investors.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.